UK Patient Receives First Dose in OATD-01 Phase 2 Sarcoidosis Trial

Molecure, a biotech firm, is at the forefront of developing breakthrough therapies for incurable diseases. The company's mission is to revolutionize treatment by identifying key proteins and mRNA involved in disease progression and inhibiting their activity with small molecules, thereby preventing and reversing the effects of these diseases.

Molecure's expertise in medicinal chemistry and pharmacology, combined with insights into novel therapeutic targets gained from leading global universities, has enabled the creation of a broad pipeline of potential drugs. These drugs are targeted at unique, previously unexplored protein targets and a platform for discovering small-molecule drugs that modulate mRNA function.

In March 2022, the company formerly known as OncoArendi rebranded as Molecure. The company has received approval to initiate a Phase II clinical trial (KITE study) for its clinical candidate OATD-01, which is being studied for the treatment of pulmonary sarcoidosis in the European Union and Norway.

Molecure has also published financial reports for the first quarter of 2024 and for the year 2023, indicating that the company is progressing according to plan with its clinical and preclinical development programs. The financial reports highlight significant acceleration in the development of these programs and plans for intensive progress in research in 2024 and 2025.

The people at Molecure are the foundation of the company's success. Its scientists are the creators of innovative ideas for new small-molecule drugs developed in their laboratories. The team works collaboratively to discover therapies for previously untreatable diseases, driven by a passion for science and a commitment to creating.

Molecure's lead drug candidate, OATD-01, is an innovative first-in-class chitinase inhibitor designed to treat sarcoidosis and other diseases characterized by chronic inflammation leading to tissue remodeling and fibrosis. In the Phase II clinical trial, patients will receive a daily oral dose of 25 mg OATD-01 or a placebo for 12 weeks. The study is a double-blind, randomized, placebo-controlled trial aimed at assessing the clinical efficacy, pharmacokinetics, pharmacodynamics, and safety of the drug.

The trial will take place in the UK, US, and EU, including Norway, and is expected to involve around 100 patients. OATD-01, a first-in-class chitotriosidase 1 (CHIT1) inhibitor, holds the potential to modify the course of sarcoidosis and other interstitial lung diseases.

Molecure's commitment to advancing the treatment of incurable diseases is evident in its ongoing clinical trials and the development of its drug candidates. The company's dedication to scientific discovery and innovation is the driving force behind its efforts to bring new therapeutic options to patients in need.